A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis:

Multiple Sclerosis Journal – Experimental, Translational and Clinical

Andrew Eisen¹  Anthony O Caggiano²  Douglas L Arnold³  James D Bowen⁴  Benjamin M Greenberg⁵ 

[1] Acorda Therapeutics Inc, Ardsley, NY, USA;Montreal Neurological Institute, McGill University, Montreal, QC, Canada;NeuroRx Research, Montreal, QC, Canada;Swedish Hospital Medical Center, Seattle, WA, USA;University of Texas SW Medical Center, Dallas, TX, USA

关键词: Clinical trial;    demyelination;    disease-modifying therapies;    multiple sclerosis;   

DOI  :  10.1177/2055217317743097

学科分类：医学（综合）

来源: Sage Journals

【 授权许可】

CC BY-NC